MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
ProPhase Labs Cost of Revenue 2011-2025 | PRPH
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 52 M | 37.1 M | 9.91 M | 7.26 M | 8.34 M | 7.92 M | 3.21 M | 1.69 M | 7.89 M | 8.36 M | 8.15 M | 6.17 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52 M | 1.69 M | 13.2 M |
Quarterly Cost of Revenue ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.01 M | 513 K | 905 K | - | 1.2 M | 1.66 M | 2.42 M | - | 6.04 M | 6.77 M | 8.78 M | - | 12.2 M | 10.4 M | 18.9 M | - | 5.5 M | 4.68 M | 6.34 M | - | 2.8 M | 2.34 M | 1.47 M | - | 1.93 M | 1.39 M | 1.8 M | - | 1.68 M | 1.93 M | 1.98 M | - | 2.61 M | 1.76 M | 686 K | - | 1.2 M | 993 K | 731 K | - | 1.67 M | 1.18 M | 2.2 M | - | 1.62 M | 1 M | 2.19 M | - | 2.13 M | 1.01 M | 2.2 M | - | 2.02 M | 1.07 M | 1.68 M | - | 1.49 M | 848 K | 1.17 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.9 M | 513 K | 3.02 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.68 | -3.44 % | $ 181 M |  Canada |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 4.76 | -1.14 % | $ 627 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Pacira BioSciences
PCRX
|
170 M | $ 26.64 | 1.33 % | $ 1.23 B | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 12.27 | 7.44 % | $ 628 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 3.52 | -2.07 % | $ 4.37 M | USA |
 |
Evolus
EOLS
|
84 M | $ 7.14 | 1.42 % | $ 443 M | USA |
 |
Harrow Health
HROW
|
39.6 M | $ 46.39 | -1.43 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Veru
VERU
|
11 M | $ 2.39 | -1.24 % | $ 322 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.81 | -5.99 % | $ 402 M | Canada |
 |
cbdMD
YCBD
|
7.49 M | $ 1.18 | -3.28 % | $ 5.09 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.04 | 20.16 % | $ 42.7 M | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
2.83 B | $ 12.77 | -2.85 % | $ 1.75 B | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.96 | -11.31 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
480 M | $ 11.19 | -7.9 % | $ 6.92 B | Canada |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
7.87 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
9.77 B | $ 11.65 | - | $ 14.1 B | USA |